Novel Treatment for Syndromic Ichthyoses

CHILD Syndrome Clinical Trial

Official title: Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses

Status Withdrawn

Clinical Trial Summary

This is an open label-pilot study to assess the efficacy and safety of a novel cholesterol-lovastatin topical solution in children with rare syndromic ichthyoses. Often times, these children have difficulty in finding easily applied treatments to make their psoriasiform and ichthyotic plaques more manageable. We propose the use of a cholesterol-lovastatin topical solution as a treatment option with the hypothesis that it will lead to regression of involved areas and decreased erythema and warty-like appearance of the plaques. We plan to enroll children with syndromic ichthyoses over the age of 1 year for a 12 month study with a total of 5 visits and 5 phone calls.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• CHILD Syndrome
• Conradi Syndrome
• Ichthyosis
• Smith Lemli Opitz Syndrome
• Smith-Lemli-Opitz Syndrome
• Syndrome
• Syndromic Ichthyoses

• NCT number: NCT01110642
• Study type: Interventional
• Source: Northwestern University
• Status: Withdrawn
• Phase: Phase 2
• Start date: July 2011